SLU-PP-332

SLU-PP-332 is the most pharmacologically novel compound in this reference and the one where the gap between scientific excitement and clinical readiness is most extreme. It does something no other compound here does: directly activates the transcriptional master switch of aerobic exercise. The biology is real. The translation to humans is a complete unknown.

The central tension resolved: A sedentary mouse given SLU-PP-332 runs 70% farther than an untreated sedentary mouse. This is a genuine and dramatic finding. The mechanism is confirmed, the ERRα specificity is proven, the gene expression signature is the aerobic exercise program. WADA banned it before a single human received it. Metabolite detection assays are in development. A Phase 1 trial has not been registered. The community is using it at doses potentially 3,500-12,000-fold below the animal study doses, via an oral route rather than intraperitoneal injection, with no pharmacokinetic reference for whether they are achieving any receptor activation at all, and no safety monitoring for the cardiac signal that the preclinical work identified. The 70% endurance figure is from mice. Whether any humans have experienced any endurance benefit at community doses is entirely unknown — the consistent self-reports of improved aerobic performance may reflect genuine ERR activation at sub-animal-study-doses, or they may reflect expectation effects in a highly motivated self-experimenting population, or some combination. There is no way to know without controlled data.

The strongest argument for SLU-PP-332: the mechanism is the most direct and complete exercise mimicry ever characterized pharmacologically. The target (ERRα) is the right target. The downstream biology is the right biology. The animal data is the most dramatic endurance enhancement in the exercise mimetic literature. The compound is orally bioavailable. If a Phase 1 trial establishes safety and a Phase 2 establishes that the gene expression findings translate to human endurance improvement — this would be one of the most significant metabolic therapeutic discoveries of the century.

The strongest argument for caution: every positive statement in the previous paragraph is conditional on human translation that has not occurred. The cardiac signal is uncharacterized in humans. The dose that produces any ERR activation in humans is unknown. The community is taking what may be pharmacologically inert doses of a compound for which no human reference data exists. The WADA ban is appropriate and the detection infrastructure is being built. Any legitimate therapeutic application is years away from approval even if Phase 1 goes perfectly.